Progetto Laser, lotta alla sepsi in Emilia-Romagna - apicella

Bibliografia
Progetto LaSER. Lotta alla sepsi in Emilia-Romagna
• Abraham E., Laterre P.F., Garg R., Levy H., Talwar D., Trzaskoma B.L., Francois B., Guy
J.S., Bruckmann M., Rea-Neto A., Rossaint R., Perrotin D., Sablotzki A., Arkins N.,
Utterback B.G., Macias W.L., Administration of Drotrecogin Alfa (Activated) in Early Stage
Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with
severe sepsis and a low risk of death. N Engl J Med, 353 (13): 1332-1341, 29 Sep 2005.
• Agenzia Italiana del Farmaco. Monitoraggio dell’uso di Xigris nelle terapia intensive
italiane. Risultati della seconda fase di raccolta dei dati. Bollettino di Informazione sui
Farmaci, XIII (2): 70-75, 2006.
• Annane D., Sebille V., Charpentier C., Bollaert P.E., Francois B., Korach J.M., Capellier
G., Cohen Y., Azoulay E., Troche G., Chaumet-Riffaut P., Bellissant E. Effect of treatment
with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic
shock. JAMA. The Journal of the American Medical Association, 288 (7): 862-871, 21 Aug
2002.
• Annane D., Bellissant E., Bollaert P.E., Briegel J., Keh D., Kupfer Y. Corticosteroids for
treating severe sepsis and septic shock. Cochrane Database Syst Rev, 1): CD002243-,
2004.
• Annane D., Bellissant E., Cavaillon J.M. Septic shock. Lancet, 365 (9453): 63-78, 1 Jan
2005.
• Barton P., Kalil A.C., Nadel S., Goldstein B., Okhuysen-Cawley R., Brilli R.J., Takano
J.S., Martin L.D., Quint P., Yeh T.S., Dalton H.J., Gessouron M.R., Brown K.E., Betts H.,
Levin M., Macias W.L., Small D.S., Wyss V.L., Bates B.M., Utterback B.G., Giroir B.P.
Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in
children with severe sepsis. Pediatrics, 113 (1 Pt 1): 7-17, 2004. PMID: 14702440
[PubMed - indexed for MEDLINE]
• Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A.,
Steingrub J.S., Garber G.E., Helterbrand J.D., Ely E.W., Fisher C.J. Jr. Efficacy and safety
of recombinant human activated protein C for severe sepsis. N Engl J Med, 344 (10):
699-709, 8 Mar 2001.
• Bernard G.R., Margolis B.D., Shanies H.M., Ely E.W., Wheeler A.P., Levy H., Wong K.,
Wright T.J., Extended Evaluation of Recombinant Human Activated Protein C United
States Investigators. Extended evaluation of recombinant human activated protein C
United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of
drotrecogin alfa (activated) in severe sepsis. Chest, 125 (6): 2206-2216, 2004. PMID:
15189943 [PubMed - indexed for MEDLINE]
Dossier 143
101